Cargando…

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer

High expression of immune checkpoint receptors (ICRs) in the tumor microenvironment regulates the anti-tumor response. In this study, the differential expressions of ICRs on tumor-infiltrating lymphocytes (TILs) in patients with early-stage breast cancer were investigated. The study included 32 pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mollavelioglu, Baran, Cetin Aktas, Esin, Cabioglu, Neslihan, Abbasov, Aykhan, Onder, Semen, Emiroglu, Selman, Tükenmez, Mustafa, Muslumanoglu, Mahmut, Igci, Abdullah, Deniz, Gunnur, Ozmen, Vahit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587596/ https://www.ncbi.nlm.nih.gov/pubmed/36271406 http://dx.doi.org/10.1186/s12957-022-02810-z

Ejemplares similares

Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?
por: Emiroglu, Selman, et al.
Publicado: (2023)

Single axillary incision endoscopic surgery and liposuction for gynecomastia
por: Tukenmez, Mustafa, et al.
Publicado: (2023)

TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
por: Cabioglu, Neslihan, et al.
Publicado: (2021)

Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer
por: Cabioglu, Neslihan, et al.
Publicado: (2023)

Ozone therapy as a novel complementary therapeutic approach in refractory idiopathic granulomatous mastitis
por: Cabioglu, Neslihan, et al.
Publicado: (2023)

Breast cancer risk factors in Turkish women – a University Hospital based nested case control study
por: Ozmen, Vahit, et al.
Publicado: (2009)

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
por: Oner, Gizem, et al.
Publicado: (2021)

Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
por: Oner, Gizem, et al.
Publicado: (2023)

Favorable Outcome with Close Margins in Patients Undergoing Nipple/Skin Sparing Mastectomy with Immediate Breast Reconstruction: 5-year Follow-up
por: Özkurt, Enver, et al.
Publicado: (2018)

Is the thymidine labeling index a good prognostic marker in breast cancer?
por: Sen-Oran, Ebru, et al.
Publicado: (2007)

Local steroid injection in severe idiopathic granulomatous mastitis as a new first-line treatment modality with promising therapeutic efficacy
por: Cabioglu, Neslihan, et al.
Publicado: (2023)

Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer
por: Kizildag Yirgin, Inci, et al.
Publicado: (2020)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
por: Jin, Shengming, et al.
Publicado: (2023)

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
por: Takamatsu, Kimiharu, et al.
Publicado: (2021)

DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

Incarcerated appendix epiploica in a right inguinal hernia sac
por: Abbasov, Aykhan, et al.
Publicado: (2021)

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

A rare pinch-off case embolized to the pulmonary artery
por: Abbasov, Aykhan, et al.
Publicado: (2023)

Poor Biological Factors and Prognosis of Interval Breast Cancers: Long-Term Results of Bahçeşehir (Istanbul) Breast Cancer Screening Project in Turkey
por: Cabioğlu, Neslihan, et al.
Publicado: (2020)

Diagnostic Performance of AI for Cancers Registered in A Mammography Screening Program: A Retrospective Analysis
por: Kizildag Yirgin, Inci, et al.
Publicado: (2022)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

PD1, CTLA4 and TIGIT Expression on T and NK Cells in Granulomatous Diseases: Sarcoidosis and ANCA-Associated Vasculitis
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
por: Malinga, Nonkululeko Z., et al.
Publicado: (2022)

Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice
por: Zhang, Yiwei, et al.
Publicado: (2019)

CD4(+) T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
por: Fromentin, Rémi, et al.
Publicado: (2016)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Effect of leaching residual methyl methacrylate concentrations on in vitro cytotoxicity of heat polymerized denture base acrylic resin processed with different polymerization cycles
por: BURAL, Canan, et al.
Publicado: (2011)

Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response
por: Yang, Riyao, et al.
Publicado: (2023)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment
por: Aydiner, Adnan, et al.
Publicado: (2015)

Cytokine Contents in Chronic Lymphocytic Leukemia: Association with ZAP70 Expression
por: Işıksaçan, Nilgün, et al.
Publicado: (2016)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
por: Yu, Lihua, et al.
Publicado: (2021)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma
por: Xie, Xiaolin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0kuph6em6u6tpqj06eal7am57q